David Ryan Purdue Sells 5,230 Shares of AbbVie (NYSE:ABBV) Stock

March 7, 2026 by InsiderTrades.com

Key Points

Insider sale: SVP David Ryan Purdue sold 5,230 AbbVie shares on March 4 at an average price of $233.56 for $1,221,518.80, cutting his direct ownership by 66.34% to 2,654 shares.
AbbVie beat Q4 expectations with EPS of $2.71 and revenue of $16.62 billion (up 10% YoY) and issued FY‑2026 guidance of 14.37–14.57 EPS (Q1 guidance 2.97–3.01).
The company declared a quarterly dividend of $1.73 (annualized $6.92, ~3.0% yield) but carries a very high payout ratio (DPR 293.22%) and recently completed an $8 billion senior notes offering, raising leverage concerns.

AbbVie Inc. (NYSE:ABBV - Get Free Report) SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

AbbVie Stock Down 0.8%

Quiet Outperformance From an Overlooked Dividend ETF

Shares of NYSE ABBV opened at $230.41 on Friday. The stock has a market cap of $407.40 billion, a P/E ratio of 97.63, a P/E/G ratio of 0.81 and a beta of 0.34. The firm's 50-day simple moving average is $224.72 and its 200 day simple moving average is $223.97. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 EPS. AbbVie's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price objective for the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. The Goldman Sachs Group reiterated a "neutral" rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Finally, BMO Capital Markets reissued an "outperform" rating and issued a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $253.15.

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

Check Out Our Latest Stock Report on AbbVie

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I'd consider a buy-and-never-sell
Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis - Abbvie Inc.
Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently bought and sold shares of the stock. Diversified Trust Co boosted its position in AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company's stock valued at $13,215,000 after purchasing an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new position in AbbVie in the 3rd quarter worth about $720,000. Railway Pension Investments Ltd increased its position in AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company's stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors raised its stake in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company's stock worth $26,378,000 after purchasing an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co raised its stake in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company's stock worth $7,434,000 after purchasing an additional 15,502 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.